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Alternative Natural Management 
of Dyslipidemia
Abdullah Glil Alkushi
Abstract
In hypercholesterolemic patients, besides therapeutic treatments, alternative 
treatments can be used such as lifestyle changes, e.g. avoiding smoking, regular exer-
cise, and consuming a diet rich in fiber and low in trans saturated and saturated fats. 
There are also certain plant products, such as the gum residue guggulipid, that are 
used in India as a traditional medicine to reduce blood cholesterol levels. Similarly, 
red yeast rice and rice bran oil have been observed to reduce elevated cholesterol 
levels. Other herbal products have also been investigated for their role in lowering 
cholesterol levels, as well as various other herbs and spices such as ginger and tur-
meric. Another herbal remedy available for reducing high cholesterol levels is the leaf 
extract of Cynara scolymus, commonly known as artichoke thistle. Cynara cardunculus 
var. scolymus, or globe artichoke, is mainly cultivated as a food crop. It has an impor-
tant effect on reducing plasma cholesterol and low-density lipoprotein levels.
Keywords: alternative medicine, lifestyle changes, natural plants,  
Chinese medicine, vitamins and minerals
1. Dyslipidemia and Lifestyle
Hypercholesterolemia (HC) is defined as the increase in the levels of choles-
terol in the blood. As per the recommendation of the expert panel of the National 
Cholesterol Education Program, desirable blood cholesterol levels should be 
<200 mg/dL. Levels ranging between 200 and 239 mg/dL are considered as bor-
derline for cholesterol levels, and individuals with blood cholesterol levels above 
240 mg/dL are considered hypercholesterolemic [1]. HC occurs due to both envi-
ronmental and genetic factors [2]. According to familial HC, environmental factors 
mainly include obesity and diets rich in saturated fats, whereas genetic factors com-
prise the additive effects of several genes or defects in a single gene [3–5]. Elevated 
cholesterol levels in the blood not only cause coronary heart disease but can also lead 
to stroke and damage to the brain [6, 7]. High cholesterol has also been linked to 
peripheral vascular disease, in which fat is deposited mainly in the arteries that lead 
to the legs and feet [8]. HC is also linked to type 2 diabetes and hypertension [9, 10].
In hypercholesterolemic patients, besides therapeutic treatments, alternative 
treatments can be used such as lifestyle changes, e.g. avoiding smoking, regular 
exercise, and consuming a diet high in fiber and low in trans saturated and satu-
rated fats. Similarly, red yeast rice and rice bran oil have been observed to reduce 
elevated cholesterol levels. Other herbal products have also been investigated for 
their role in lowering cholesterol levels, as well as various other herbs and spices 
such as ginger and turmeric.
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Another herbal remedy is the leaf extract of Cynara scolymus, commonly known 
as artichoke thistle. Cynara cardunculus var. scolymus, or globe artichoke, is mainly 
cultivated as a food crop. It has important effects in reducing plasma cholesterol 
and low-density lipoprotein (LDL) levels. Also, many vitamins and minerals help to 
reduce and control fat and cholesterol levels.
These will be discussed in this chapter.
1.1 Lifestyle changes
One of the most important things in the natural treatments of dyslipidemia is to 
reduce body weight and take regular exercise [11], which will help to regulate blood 
cholesterol [12] and decrease the high risk of developing cardiovascular diseases, 
especially coronary heart disease [13].
1.2 Stopping smoking
This is important in controlling high blood cholesterol, decreasing the risk 
of coronary heart disease, and improving high-density lipoprotein (HDL) cho-
lesterol [14]. The mechanism of cigarette smoking will have an effect on lipid 
profile and enhance oxidation of plasma LDL, which leads to endothelial function 
impairment.
1.3 Alcohol intake
Alcohol has adverse effects on cholesterol and lipid levels, including raising 
serum triglyceride and HDL cholesterol levels. It has a minimum effect on LDL 
cholesterol but has effects on the body, including hepatic toxicity, cardiomyopathy, 
impaired reflexes, and psychosocial problems [15].
1.4 Exercise
Exercise is important in reducing the chance of developing heart disease. It is 
also important to reduce body weight, which can lead to reduced levels of fat and 
cholesterol [11].
Physical activity and exercise can be an important factor to improve cholesterol 
levels, increase HDL, and reduce LDL and triglycerides [16].
Aerobic exercise can generally improve lipid profile [17].
Moderate intensity aerobic exercise and an increase in physical activity in healthy 
people for more than 30 minutes for 5 days a week are important to maintain low 
LDL, cholesterol, and triglyceride levels, as well as increase HDL levels [18, 19].
In dyslipidemia especially in older or disabled individuals, increasing physical 
activity for more than 30 minutes for 5 days a week, moderate-intensity aerobic 
exercise [19], and high-intensity resistance exercises can all reduce LDL and triglyc-
erides and increase HDL [20].
The beneficial effects of regular physical activity and exercise on cholesterol 
levels are important in the management of dyslipidemia and can lead to reducing 
the risks of heart attacks, strokes, and coronary heart disease.
2. Food that should be avoided
1. Food containing too much sugar and carbohydrates, which stimulate the liver 
to produce more cholesterol, should be avoided.
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2. Hydrogenated and trans fats increase cholesterol and the risk of cardiovascular 
diseases.
3. Red meat and animal products increase the risk of dyslipidemia.
3. Food and dyslipidemia
Foods that help to decrease dyslipidemia are shown in Tables 1 and 2.
3.1 Dietary fiber intake
Dietary fiber (DF) intake provides many health benefits. However, the aver-
age fiber intake for US children and adults is less than half of the recommended 
levels. Individuals with high intakes of DF appear to be at significantly lower risk 
for developing coronary heart disease, stroke, hypertension, diabetes, obesity, and 
certain gastrointestinal diseases. Increasing fiber intake lowers blood pressure and 
serum cholesterol levels.
The effect of dietary soluble fiber on serum cholesterol levels has been exten-
sively documented and promoted. The main mechanisms for the cholesterol-
lowering effects of water-soluble and -insoluble DFs include binding and 
excretion of bile acids (BAs) in the small intestine. The cholesterol-reducing 
effect of water-insoluble DF, such as lignin or citric fiber, is rather low compared 
to water-soluble DF and is mainly based on direct binding of BAs. In the small 
intestine the BAs are bound to the insoluble DF and excreted from the enterohe-
patic circulation together with the undigested DF, which results in a lowering of 
blood cholesterol levels.
In addition, soluble fibers are known to bind to BAs in the small intestine, 
thereby removing them from the body and reducing the rate of BA recycling. The 
loss of BAs in the stool stimulates the liver to increase cholesterol uptake from the 
circulation to replenish the BA supply. As a result, concentrations of serum total 
and LDL cholesterol are reduced, while HDL cholesterol and triglycerides are 
generally unaffected [21].
3.2 Omega-3
Omega-3 fatty acids are presented in two formulas:
• Docosahexaenoic acid (DHA)
• Eicosapentaenoic acid (EPA)
Omega-3 fatty acids are important in reducing triglycerides and non-HDL 
cholesterol [22–24].
Reducing triglycerides and cholesterol helps to reduce atherosclerosis [25–28].
Using omega-3 fatty acids has benefits in metabolic abnormality associated with 
non-alcoholic fatty liver in patients with hyperlipidemia [29].
3.3 Garlic
Garlic (Allium sativum) belongs to onion genes. It used as an herb medication 
for various diseases. It has major roles in decreasing risk factors of cardiovascular 
diseases like high blood pressure and high serum lipids [30–33].
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Garlic reduces cholesterol, LDL, and triglyceride levels by inhibiting cholesterol 
biosynthesis in the liver and LDL oxidation [34–38].
There are a few side effects associated with using garlic such as allergic dermati-
tis [39] and its interference with oral anticoagulant drugs [39].
3.4 Read yeast rice
Red yeast rice is a product of rice and is found in China and many Asian coun-
tries where it is used as a traditional medicine [40, 41].
Name Type Effects on lipid profile
Vitamin B3 (niacin) Water-soluble 
vitamin
Lowers LDL, cholesterol, and triglyceride levels
Vitamin B5 Water-soluble 
vitamin
Lowers LDL, cholesterol, and triglyceride levels
Vitamin C Water-soluble 
vitamin
Protects against LDL oxidation
Vitamin D Fat-soluble vitamin Reduces the risk of arterial blockage
Magnesium Mineral Protects against LDL oxidation
Manganese Mineral Protects against LDL oxidation
Zinc Mineral Protects against dangerous lipoproteins and promotes 
HDL
Selenium Mineral Protects against dangerous lipoproteins
Copper Mineral Protects against dangerous lipoproteins
Coenzyme Q10 Mineral Protects against dangerous lipoproteins
Chromium Mineral Increases HDL level
Choline Mineral Controls HDL level
Inositol Mineral Lowers LDL and triglyceride levels
Lipoic acid Mineral Lowers LDL and protects against cholesterol oxidation
Carnitine Mineral Lowers LDL and triglyceride levels
Table 2. 
Vitamins and minerals and their effects on lipid profiles.
Plant name Type Effects on lipid profile
Dietary fiber Food Lowers LDL and cholesterol levels
Omega-3 Food Lowers cholesterol and triglyceride levels
Garlic Food Lowers cholesterol and triglyceride levels
Red yeast rice Food Lowers cholesterol level
Chinese medicine Herbal Lowers hyperlipidemia
Artichoke Food Lowers cholesterol level
Fenugreek Herbal Lowers cholesterol level
Gum residue guggulipid Herbal Lowers LDL and cholesterol levels
Ginger Food Lowers cholesterol level
Table 1. 
Foods and herbals and their effects on lipid profiles.
5Alternative Natural Management of Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.82430
Biochemically it contains polyketides, unsaturated fatty acids, phytoster-
ols, pigments, and monacolins [41, 42]. It lowers cholesterol by inhibiting 
5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is 
the rate-limiting step for cholesterol synthesis in the liver. This component, 
especially monacolins, is chemically similar to lovastatin (a drug used to treat 
hypercholesteremia) [41, 43].
3.5 Chinese medicine
Traditional Chinese medicine (TCM) has been used in clinical practice for many 
centuries. Chinese medicine has shown good effects for human health and treating 
many diseases. Recently, TCM has shown a beneficial effect for treating dyslipidemia; 
however, its mechanism remains unclear or totally unknown. Many studies on dyslip-
idemia with a single Chinese herb showed that TCM can improve phlegm, dampness, 
and blood stasis syndromes in patients with hyperlipidemia, therefore it has a benefi-
cial effect for lowering hyperlipidemia monomers or effective extracts [44–46].
One study [46] showed that Chinese herbs, which have effects on hyperlipid-
emia, have four beneficial characteristics:
1. Clearing heat and removing toxicity, for example, Radix et Rhizoma Rhei, 
Rhizoma Polygoni Cuspidati, Semen Cassia, Coptis chinensis, Scutellaria 
baicalensis, Gynostemma pentaphyllum, and Radix Puerariae.
2. Promoting blood circulation and removing blood stasis, for example, Fructus 
crataegi, red yeast rice, Rhizoma, Radix Salvia miltiorrhizae, and Turmerone.
3. Eliminating dampness and phlegm, for example, Rhizoma Alismatis, plantain 
seed, and folium nelumbinis.
4. Increasing body energy, for example, Radix Astragali, Radix Ginseng, and 
Radix polygoni multiflori.
3.6 Artichoke
Another herbal remedy available for reducing high cholesterol levels is the leaf 
extract of Cynara scolymus, commonly known as artichoke thistle. Cynara carduncu-
lus var. scolymus, or globe artichoke, is mainly cultivated as a food crop. It is a peren-
nial plant that is largely native to the Mediterranean region in Southern Europe and 
Northern Africa, and the Canary Islands. In addition to food, artichoke is used in 
tea and liqueur preparation. Studies on the medicinal properties of artichoke have 
been continuing over the last six decades. Several in vitro and in vivo studies have 
investigated the effect of artichoke leaf extract (ALE), especially cymarine, in 
reducing plasma cholesterol levels [47–50]. Along with cymarine, the antiathero-
sclerotic effect of luteolin-rich artichoke extract reduces LDL oxidation in a dose-
dependent manner [51]. A dose-dependent inhibition of cholesterol biosynthesis, 
using ALE, was also shown in primary-cultured rat hepatocytes [52].
In addition to in vitro and in vivo studies, randomized controlled studies have 
assessed the effects of the oral administration of ALE in hypercholesterolemic 
patients. Bundy et al. assessed the effect of ALE on plasma lipid levels and general 
well-being in healthy individuals with mild to moderate HC [53]. The participants 
of the study received 1280 mg of ALE daily (four tablets of 320 mg) for 12 weeks. 
The majority of participants were females, and almost 90% of them were more 
than 40 years old. The plasma cholesterol levels were found to be reduced by 4.2% 
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in the group administered ALE, whereas they increased by 1.9% in the placebo 
group. No significant difference in LDL cholesterol, HDL cholesterol, or triglyc-
erides was observed between the groups. Englisch et al. conducted a similar study 
among 18–70-year-old hypercholesterolemic patients [54]. In addition to treatment 
with cholesterol-reducing drugs, participants were prohibited from antibiotic 
treatment. The intervention group received 1800 mg of ALE for 6 weeks. Total 
cholesterol levels were reduced by 18.5% in the group administered with ALE as 
compared to a 8.6% reduction in the placebo group. In addition to atherosclerosis, 
HC can affect organs such as kidneys. Studies in rats have shown that cholesterol 
can increase the incidence of glomerulosclerosis, and in vitro cell culture studies 
using human glomerular cells revealed the possible mechanisms that are involved 
in lipid-influenced glomerular damage [55]. Another study showed that treating 
HC in obese rats reduced their glomerular injuries [56]. Similar observations have 
also been made in studies with humans. Individuals with high triglycerides or a 
lecithin–cholesterol acyltransferase deficiency gradually developed renal failure 
due to glomerulosclerosis [57].
C. cardunculus leaf extract (CCL) not only has cholesterol-reducing capacity but 
also reduces blood glucose levels and repairs impaired kidney function and damage. 
These findings are significant particularly because HC results in further complications 
such as diabetes and kidney damage, both of which can be treated effectively with 
artichoke [50].
The hypercholesterolemic properties of artichoke involve inhibition of the 
enzyme HMG-CoA reductase. By lowering blood cholesterol levels and improv-
ing lipid profile, experts believe that artichoke can reduce the risks of arterio-
sclerosis and coronary heart disease and found that both CCL and C. cardunculus 
pulp extract.
decrease the concentration of the respective enzymes (an increase in levels of 
aspartate transaminase (AST), alanine aminotransferase (ALT), and alkaline phos-
phatase (ALP) are indicators of liver dysfunction), hence serving hepatoprotective 
and regenerating effects [58]. Thus, it was concluded that artichoke has a beneficial 
effect on cardiovascular and liver disease.
3.7 Fenugreek seeds
Fenugreek (Trigonella foenumgraecum) has an effect on cholesterol and blood 
sugar. It is a good source of dietary fiber and has beneficial effects on decreasing 
cholesterol levels in blood and the liver [59, 60].
The mechanism of the lipid-lowering effect of fenugreek seeds is due to the presence 
of 4-hydroxyisoleucine, a branched chain amino acid [61], and its action on adipocytes 
and liver cells, which leads to decreased triglycerides, cholesterol, and LDL [62, 63].
3.8 Gum residue guggulipid
A gum resin of the tree Commiphora mukul, used for the management of obesity 
and lipid disorders, is centuries old [64]. The extract of this gum resin, designated 
guggulipid, has lipid-lowering effects in normal and hyperlipidemic animals (rats, 
rabbits, and monkeys) [65, 66].
In humans, many studies of the effect of gum resin gumsome in response to 
guggul treatment were observed in of patients in India [67].
In the United States, studies showed that 18% of patients showed a response to 
guggulipid treatment, with a decrease in LDL levels of more than 5% [68].
Variations in the results of clinical studies are due to many factors such as ethnic 
and genetic backgrounds, dietary restraints, and lifestyle [69].
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3.9 Ginger
Ginger (Zingiber officinale) is a traditional natural plant, which has many 
characteristics such as decreasing lipid levels, antiplatelet aggregation, and 
antioxidant and anticarcinogenic qualities [70]. Several studies show that ginger 
can lower high cholesterol levels in animals. In humans a few study results showed 
the effects of using ginger in patients with high cholesterol and in the treatment of 
dyslipidemia [71].
4. Vitamins and minerals
4.1 Vitamin B3 (niacin)
Niacin is a water-soluble vitamin. It effectively lowers the atherogenic 
lipoprotein(a) by decreasing the rate of synthesis in the liver and lowering the 
level of cholesterols as well as triglycerides [72, 73]. It is important in reducing the 
incidence of cardiovascular disease.
4.2 Vitamin B5
Vitamin B5 is a water-soluble vitamin, which is also called pantothenic acid. It is 
important in the synthesis of coenzyme A, as well as lowering LDL metabolism and 
reducing triglycerides [74, 75].
4.3 Vitamin C
Vitamin C is a water-soluble vitamin and is essential for repairing tissues and 
enzyme production. It has a role in lipid metabolism, protects LDL from oxidation, 
and lowers atherosclerosis and lipoprotein(a) in some people [76, 77].
4.4 Vitamin D
Vitamin D is a fat-soluble vitamin and has an important function in the body, 
including calcium homeostasis and suppressing foam cell formation, which reduces 
the risk of arterial blockage [78, 79] therefore reducing cardiovascular disease 
problems.
4.5 Magnesium
Magnesium protects LDL from being oxidized [80, 81].
4.6 Manganese
Manganese is a cofactor to the antioxidant superoxide dismutase that repairs 
damage to blood vessels caused by oxidized LDL [82, 83].
4.7 Zinc
Zinc protects against dangerous lipoproteins that lead to vascular inflammation 
and plaque formation. It also controls the gene that makes HDL [84, 85].
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4.8 Selenium
Selenium prevents postprandial change in lipoproteins, which makes them easy 
to oxidize and become harmful [86, 87].
4.9 Copper
Many copper-dependent enzymes affect lipoprotein metabolism that build up 
fats and cholesterol in arteries [88–90].
4.10 Coenzyme Q10
Coenzyme Q10 lowers lipoprotein(a) and improves dyslipidemia medicine [91, 92].
4.11 Chromium
Chromium increases HDL levels and cooperates with niacin (B3) for dyslipid-
emia [93–95].
4.12 Choline
Choline controls HDL metabolism due to the enzyme lecithin cholesterol acyl-
transferase that has beneficial effects on lipoprotein metabolism [96, 97].
4.13 Inositol
Inositol lowers LDL levels, especially in patients with metabolic syndrome. It 
also lowers triglyceride levels [98–100].
4.14 Lipoic acid
Lipoic acid lowers LDL levels and protects against oxidized cholesterol [101, 102].
4.15 Carnitine
Carnitine lowers triglycerides, LDL, and the atherogenic lipoprotein(a) by 
transporting fatty acids into cells so that they can be used as energy [103–105].
5. Conclusion
Besides pharmacological treatments for HC, using alternative treatments may 
help to increase the effectiveness of drugs. Alternative treatments can help to alter 
sedentary lifestyles and include exercise, stopping smoking, and eating a number of 
foods (omega-3, garlic, red yeast rice), herbs (Chinese medicine), vitamins (B, B5, 
C, and D), and many minerals.
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